The tech transfer mistakes that cost biotech companies months usually begin before the first engineering batch: the receiving site lacks enough process knowledge, equipment fit, analytical readiness, or decision authority to reproduce the process reliably. A disciplined biotech tech transfer closes those gaps before manufacturing work reaches the schedule.
You can lose weeks to repeated experiments, method failures, unresolved deviations, and validation rescheduling when the transfer is treated as a document handoff. This article explains where those delays begin, how they spread across manufacturing and quality operations, and what you can do before they affect supply commitments. The goal is to help you move from development to routine production with fewer surprises.
Mistake: Starting Before The Transfer Scope Is Defined
A transfer can look active long before it’s ready. Meetings are scheduled, documents are shared, and batch dates are discussed, but the sending and receiving sites haven’t agreed on what success means. Without a written scope, teams make different assumptions about deliverables, ownership, acceptance criteria, and required evidence.
Your transfer plan should identify the product, process stage, facilities, analytical procedures, packaging operations, cleaning requirements, computerized systems, and validation activities involved. It should also name the people responsible for technical decisions, quality approvals, document updates, and deviation resolution. If a Contract Development and Manufacturing Organization (CDMO) is involved, responsibilities must remain specific rather than being hidden inside broad contract language.
Set readiness gates before scheduling engineering or qualification batches. A useful gate confirms that major risks have owners, prerequisite documents are approved, materials are available, equipment is ready, and analytical work can support sample testing. This prevents calendar pressure from turning unfinished preparation into manufacturing delays.
Mistake: Treating Documentation As The Entire Knowledge Package
Approved documents rarely contain every detail required to run a biological process at another site. Development scientists and experienced operators often rely on knowledge that never reached the batch record: mixing observations, sampling sensitivities, visual endpoints, hold-time concerns, equipment behavior, and responses to small process shifts. Sending procedures without that operating knowledge leaves the receiving team to rediscover it.
Build the transfer package around decisions, not document volume. Explain why process parameters were selected, which ranges have supporting data, what failure modes appeared during development, and which product attributes are sensitive to variation. Include development reports, scale-up studies, deviation histories, technical reports, validation records, representative batch data, and relevant Corrective and Preventive Action (CAPA) records.
Review documents for consistency before release. A specification, development report, batch record, and analytical procedure can describe the same requirement differently after years of separate revisions. Those conflicts often surface during protocol approval or batch execution, when correcting them requires formal change control and another review cycle.
Mistake: Skipping The Receiving-Site Gap Assessment
A process that works at the sending site won’t automatically work on equipment with different geometry, control ranges, automation, or sampling access. The receiving site needs a structured comparison of facilities, utilities, equipment, materials, personnel capability, and quality systems. Completing that assessment late turns predictable differences into urgent deviations.
Compare more than equipment names and nominal capacities. Review vessel dimensions, impeller design, mixing performance, heat-transfer capability, sensor location, pump type, transfer-line length, filter area, software configuration, alarm limits, and data collection. For biological manufacturing, small physical differences can change shear exposure, temperature control, oxygen transfer, recovery, or process duration.
Classify every identified gap by its potential effect on product quality, process performance, validation, and operator safety. Some gaps can be addressed through documented equivalence, operating adjustments, or added controls. Others require equipment modification, qualification work, supporting studies, or a revised process strategy before the site can execute the transfer.
Mistake: Scaling The Process With Simple Ratios
Scale-up isn’t achieved by multiplying every input by the same factor. Volume changes can affect mixing, mass transfer, heat transfer, filtration, centrifugation, chromatography loading, and processing time. If you scale from batch size alone, the commercial process may operate under physical conditions that weren’t represented during development.
Start with the process mechanisms that influence product quality and performance. Determine which parameters should remain constant, which should scale, and which require equipment-specific adjustment. Your decisions should connect development knowledge, risk assessment, process characterization, and the proposed control strategy.
Plan engineering studies around the remaining uncertainty. A run should answer defined technical questions rather than serve as an expensive rehearsal with vague goals. Specify what data will be collected, how results will be evaluated, and what decision each result supports before material enters the suite.
Mistake: Leaving Analytical Method Transfer Until Late
Manufacturing can’t progress faster than the laboratory supporting it. If analytical methods aren’t ready, you can’t release raw materials, assess in-process samples, close deviations, evaluate batch performance, or make timely disposition decisions. Late analytical method transfer can leave completed batches waiting for results.
An executable method needs more than a short sequence of laboratory steps. It should define the analytical principle, equipment, reagents, reference standards, sample preparation, operating parameters, calculations, system suitability criteria, acceptance criteria, storage conditions, and handling precautions. A competent analyst at the receiving laboratory should be able to reproduce the method without relying on undocumented instructions.
Use a transfer protocol that sets responsibilities, test design, sample requirements, predefined acceptance criteria, deviation handling, and reporting expectations. Check instrument compatibility and analyst training before formal testing begins. When results differ between laboratories, investigate sample handling, equipment configuration, reagent preparation, integration settings, and calculation rules instead of assuming analyst error.
Mistake: Ignoring Materials And Reference-Standard Readiness
A technically prepared facility can still miss its manufacturing slot because a required material isn’t released, qualified, or available in the correct quantity. Biological processes may depend on specialized media components, resins, filters, single-use assemblies, reference materials, and product-specific reagents. Lead times and quality review can become schedule constraints when procurement begins after the batch date is chosen.
Create a material map covering manufacturing, cleaning, sampling, testing, engineering work, qualification, and contingency quantities. Confirm supplier status, specifications, storage conditions, retest periods, shipping requirements, and release-testing needs. You should also verify whether the receiving site’s approved supplier, grade, or component configuration differs from the one used during development.
Reference standards need their own plan. Define qualification, characterization, inventory control, storage, shipment, expiry management, and replacement strategy. A laboratory can have an approved method and trained analysts yet remain unable to test samples because the required standard isn’t ready for use.
Mistake: Training People After Documents Are Approved
Document approval doesn’t prove that operators and analysts can execute the transferred process. Reading a procedure can establish awareness, but it can’t demonstrate aseptic technique, equipment setup, sampling execution, chromatography preparation, or response to process alarms. Late training pushes learning into engineering and validation batches, where errors consume material and scheduled suite time.
Match training to the task. Classroom review can cover process purpose, product risks, control logic, and escalation routes. Hands-on sessions, equipment walkthroughs, demonstrations, supervised practice, and observed execution are better suited to operational skills.
Track competence, not attendance. Confirm that personnel can perform assigned activities, recognize abnormal conditions, document work correctly, and escalate decisions to the right owner. Include manufacturing, Quality Control (QC), Quality Assurance (QA), engineering, validation, warehouse, and maintenance personnel when their work can affect transfer execution.
Mistake: Combining Troubleshooting With Validation
Process validation should confirm that the established process can operate reproducibly within approved parameters and meet predefined quality requirements. It shouldn’t become the stage where your team first discovers equipment incompatibility, unclear instructions, unstable methods, or unresolved scale-up behavior. Troubleshooting during validation creates deviations and can force protocol amendments or replacement batches.
Separate learning runs from confirmation runs. Engineering work should resolve operational uncertainty, test equipment setup, confirm sampling plans, train personnel, and collect data needed for the validation strategy. Close major technical questions before approving the validation protocol.
Set entry criteria for validation rather than relying only on a target date. Equipment qualification, method readiness, material release, approved records, trained personnel, completed risk reviews, and closed transfer actions should be checked together. If a prerequisite isn’t ready, moving the batch forward usually transfers the delay to a more expensive stage.
Mistake: Using Slow Decision And Change-Control Paths
Transfers produce questions and changes. A parameter may need clarification, equipment may require a different setup, or an analytical instruction may need correction. When no one knows who can approve a decision, issues move through long email chains and recurring meetings without reaching closure.
Define decision rights at the start. Separate routine technical questions from changes requiring formal quality review, regulatory assessment, or sponsor approval. Assign response targets based on risk and schedule impact, and maintain a visible action log with owners, due dates, dependencies, and closure evidence.
Don’t bypass formal controls to save time. Unapproved adjustments can create data-integrity concerns, document conflicts, and questions about whether the executed process matches the approved record. A well-designed change process moves urgent decisions quickly without weakening traceability.
Mistake: Managing Departments Instead Of One Transfer Plan
Manufacturing, Quality Control, Quality Assurance, validation, engineering, supply chain, and regulatory teams often maintain separate schedules. Those schedules can each appear achievable, yet the transfer fails when dependencies aren’t connected. A batch date has little value if testing, materials, equipment qualification, or document approval will finish afterward.
Build one integrated plan around deliverables and dependencies. Link facility readiness to equipment qualification, material release to manufacturing, method transfer to sample testing, and engineering results to validation approval. Include realistic review cycles for controlled documents, protocols, reports, changes, and deviations.
Use transfer metrics that reveal readiness rather than activity. Useful measures include overdue high-risk actions, unresolved equipment gaps, methods awaiting transfer, documents awaiting approval, unavailable materials, open deviations, and validation prerequisites not met. Counting meetings or uploaded files doesn’t show whether the receiving site can reproduce the process.
How Do You Prevent Biotech Tech Transfer Delays?
- Define scope, owners, and acceptance criteria.
- Transfer process knowledge, not files alone.
- Assess site and equipment gaps early.
- Prepare methods, materials, and training.
- Resolve uncertainty before validation.
Build Readiness Before You Protect The Date
The fastest biotech tech transfer is rarely the one with the earliest batch booking. You protect the schedule by defining responsibilities, transferring operating knowledge, comparing equipment, preparing analytical methods, securing materials, and training personnel before execution. Engineering work should close known technical gaps, and validation should confirm an established process rather than discover how it works. When every function follows one readiness plan, your team can identify delays early enough to act instead of finding them in the manufacturing suite.
References
- World Health Organization: Guidelines on Technology Transfer in Pharmaceutical Manufacturing
- International Council for Harmonisation: Q10 Pharmaceutical Quality System
- Food and Drug Administration: Process Validation, General Principles and Practices
- Food and Drug Administration: Analytical Procedures and Methods Validation for Drugs and Biologics
- Food and Drug Administration: Data Integrity and Compliance With Drug Current Good Manufacturing Practice
- Food and Drug Administration: Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients.
Nirdosh Jagota is Managing Partner at GRQ Biotech Advisors with 30+ years in the biotech industry. A former executive at Amgen, Genentech/Roche, Merck, and Pfizer, he has led >25 NDAs/BLAs/MAAs and hundreds of INDs across global regulatory, quality, and compliance.